Literature DB >> 35618752

Fear of safety compromise with biosimilar anti-VEGF-perception or truth.

Ashish Sharma1, Nikulaa Parachuri2, Nilesh Kumar3, Francesco Bandello4, Baruch D Kuppermann5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35618752      PMCID： PMC9582015          DOI： 10.1038/s41433-022-02117-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  6 in total

1.  Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.

Authors:  David Grabowski; Bradley Henderson; Dennis Lam; Edward C Keystone; Carter Thorne; Shahin Jamal; Janet Pope; Boulos Haraoui; Daming Lin; Leigh Revers
Journal:  Clin Rheumatol       Date:  2015-01-15       Impact factor: 2.980

2.  Biotherapeutics and immunogenicity: ophthalmic perspective.

Authors:  Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Francesco Bandello; Anat Loewenstein
Journal:  Eye (Lond)       Date:  2019-04-09       Impact factor: 3.775

3.  Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.

Authors:  Silvio Danese; Gionata Fiorino; Pierre Michetti
Journal:  J Crohns Colitis       Date:  2014-07-06       Impact factor: 9.071

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

6.  Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.

Authors:  Neil M Bressler; Miroslav Veith; Jan Hamouz; Jan Ernest; Dominik Zalewski; Jan Studnička; Attila Vajas; András Papp; Gabor Vogt; James Luu; Veronika Matuskova; Young Hee Yoon; Tamás Pregun; Taehyung Kim; Donghoon Shin; Inkyung Oh; Hansol Jeong; Mercy Yeeun Kim; Se Joon Woo
Journal:  Br J Ophthalmol       Date:  2021-10-16       Impact factor: 5.908
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.